RECURRENT/METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT/METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT/METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT/METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug HLX43 targets tough esophageal cancers
Disease control Recruiting nowThis phase 2 trial tests a drug called HLX43 in 102 people with advanced esophageal cancer that did not respond to or could not tolerate standard first-line therapy. HLX43 is an antibody-drug conjugate designed to deliver a chemotherapy agent directly to cancer cells. The study a…
Matched conditions: RECURRENT/METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New smart drug TQB6411 targets two cancer proteins in early human trial
Disease control Recruiting nowThis Phase 1 trial tests TQB6411, an antibody-drug conjugate designed to bind to EGFR and c-Met proteins on tumor cells, blocking their growth signals and releasing a toxin to kill the cells. The study will enroll 216 adults with advanced malignant tumors to find the safest dose …
Matched conditions: RECURRENT/METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC